NCT05212285Completed
Prognostic Value of Sarcopenia and Nutritional Status in Early-stage Non-small Cell Lung Cancer
Prognostic Value of Sarcopenia and Nutritional Status in Early-stage Non-small Cell Lung Cancer (Stage IA to IIIA)
Source: ClinicalTrials.gov · Last updated 1 Aug 2025
Brief summary (registry, in English)
Growing evidence has confirmed that the prognosis of lung cancer is not only related to the stage of disease, but also to the physiological and psychological situation of the patients. Malignant tumors are often associated with weakness and cachexia, leading to less physical activities and worse moods. However, few studies that have attempted to investigate the impact of nutritional status on the prognosis of NSCLC. Existing applications of nutritional scoring systems in early-stage of NSCLC are very limited. Therefore, this study aims to observe the correlation between nutritional status and the prognosis of patients with early-stage NSCLC, to clarify the value in predicting the overall survival rate and progression-free survival rate of NSCLC patients, and to offer evidence for alleviating the social and economic burden of NSCLC.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 469 (actual)
- First submitted
- 13 Jan 2022
- Start date
- 1 Jan 2020
- Primary completion date
- 30 Apr 2025
- Lead sponsor
- Fudan University
- Diseases
- Lung cancer
- NCT number
- NCT05212285
What you commit to
- Study type: Observational
- Participants enrolled: 469
- From 1 Jan 2020 to the primary completion date, 30 Apr 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Severe heart failure, acute progressive pulmonary inflammation, acute liver and kidney dysfunction in recent 2 weeks
- A history of other malignant tumors and related tumor chemotherapy within half year, and previous history of radiotherapy
Other
- Incomplete clinical and follow-up data or disagreement or inability to conduct regular follow-up CT imaging evaluation
- Unable to walk, fail to complete the walking test, and the risk of fall down
- Unable to complete BIA examination due to pacemaker implantation and other reasons
- Withdraw from the study for any reasons
Who the study is looking for
- The patients with non-small cell lung cancer diagnosed by cytology or pathology meet the standards of clinical diagnosis and treatment guidelines for lung cancer of Chinese Medical Association (2018 Edition)
- TNM staging diagnosis of lung cancer meets the stage IA-IIIA
Age in the registry: 18 years to 85 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Huadong Hospital, Fudan University Coordinator of this site? Confirm its status | Shanghai | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.